SKYGLO: Glofitamab in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma

Condition: Diffuse Large B-Cell Lymphoma

Sponsor: Hoffmann-La Roche

Full Title
Protocol GO44145: A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma

Study Treatment
CD20xCD3 bispecific antibody glofitamab in combination with Pola-R-CHP vs Pola-R-CHP alone

Eligibility/Info
Untreated CD20-positive Large B-Cell Lymphoma of one of the following types:
      - DLBCL, not otherwise specified (NOS) including germinal centre B-cell type, activated B-cell type
      - T-cell/histiocyte-rich large B-cell lymphoma
      - Epstein-Barr virus-positive DLBCL, NOS
      - Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 positive DLBCL
      - DLBCL/HGBCL with MYC and BCL2 rearrangements
      - HGBCL, NOS

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage